Trial reportDiabetes, obesity & metabolism2025
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06489457. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
Open the trial in the graphWho cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The effect of obesity interventions on male fertility: a systematic review and meta-analysis.Human reproduction update · 2026Pooled it
- Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.Diabetes, obesity & metabolism · 2025Trial
- Obesity-Related Functional Hypogonadism Requires Therapeutic Recalibration: Implications for GLP-1-Based Therapies.Andrology · 2026Article
- Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).Journal of endocrinological investigation · 2026Review
- Testosterone replacement therapy and cardiovascular safety in older men: lessons from TRAVERSE and beyond.Journal of endocrinological investigation · 2026Review
- Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.Scientific reports · 2026Article
- Article
- GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.Journal of clinical medicine · 2026Review
- Probiotics as Microbiome Modulators in Male Infertility: Rethinking Dysbiosis Across the Gut-Testis Axis.Journal of personalized medicine · 2026Review
- Review
- Misrepresentation of semaglutide in social media.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Efficacy of acupuncture in the treatment of asthenospermia in obese men: study protocol for a randomized control trial.Frontiers in medicine · 2026Article
- Treatment Options for Improving The Semen Quality in Obese Men: A Scoping Review.Journal of multidisciplinary healthcare · 2026Review
- Antidiabetic agents and male fertility: unraveling the impact of glucose-lowering therapies on sperm quality in diabetic males-a narrative review.Translational andrology and urology · 2025Review
- Can obesity pharmacotherapy be used to manage male infertility?Nature reviews. Endocrinology · 2025Article
- Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.Journal of clinical medicine · 2025 · on this mapReview
- GLP-1 and Its Analogs: Does Sex Matter?Endocrinology · 2025Review
- Diabetic testicular dysfunction and spermatogenesis impairment: mechanisms and therapeutic prospects.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo compare the effects of semaglutide and testosterone replacement therapy (TRT) on semen quality and parameters of functional hypogonadism (FH) in men with type 2 diabetes mellitus and obesity. MATERIALS AND
methodsWe designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m
resultsThe quality of baseline sperm parameters of our study cohort was poor, below the 5th percentile of reference values. In the SEMA group, there was a significant increase in morphologically normal sperm from baseline to the end of the study (2% [2; 3.5] vs. 4% [2; 5.5]; p = 0.012), whereas sperm concentration and total number decreased significantly in the TRT group. Compared to TRT, the SEMA group had a significantly higher number of morphologically normal sperm, sperm concentration and total number. Both groups experienced an increase in total testosterone and improvement in the AMS score, whereas the IIEF-15 score significantly improved only in the TRT group.
conclusionSemaglutide markedly improved sperm morphology, total testosterone levels and symptoms of hypogonadism. These findings highlight semaglutide's potential as a therapeutic approach for men with obesity-related FH who desire fertility. CLINICAL TRIAL REGISTRATION NUMBER: NCT06489457, www. CLINICALTRIALS: gov.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.